Pipeline / Status / Phase 3

INCREASE - Phase 3 clinical trial with Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatments of pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Phase 3 clinical trial with Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis (IPF).

An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).